Restart Life SciencesNMLSF PB Ratio is 1.84 as of Jul. 03, 2026, which is 10% above its 10-year median of 1.68. The stock has 3 warning signs investors should review. Among 1,228 Biotechnology companies, Restart Life Sciences ranks worse than 57% on this metric.
The historical rank and industry rank for Restart Life Sciences's PB Ratio or its related term are showing as below:
NMLSF'
s PB Ratio Range Over the Past 10 Years
Min: 0.42 Med: 1.68 Max: 10.21
Current: 0.88
During the past 13 years, Restart Life Sciences's highest PB Ratio was 10.21. The lowest was 0.42. And the median was 1.68.
NMLSF's PB Ratio is ranked worse than 57% of 1228
companies
in the Biotechnology industry
Industry Median: 2.97
vs NMLSF: 0.88
During the past 12 months, Restart Life Sciences's average Book Value Per Share Growth Rate was 225.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 100.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Restart Life Sciences was 138.90% per year. The lowest was -88.50% per year. And the median was -36.25% per year.
Back to Basics: PB Ratio
Restart Life Sciences (OTCPK:NMLSF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Restart Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Restart Life Sciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Restart Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Restart Life Sciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Restart Life Sciences (NMLSF) has a PB Ratio of 1.84 as of Jul. 03, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Restart Life Sciences and its competitors. This is 10% above median its historical median of 1.68. Over the past decade, Restart Life Sciences' PB Ratio has ranged from 0.42 to 10.21. According to the industry distribution chart, Restart Life Sciences ranks #700 out of 1228 companies in the Biotechnology industry, placing it in the top 57%.
Is Restart Life Sciences' PB Ratio too high?
Restart Life Sciences' current PB Ratio of 1.84 is 10% above median its 10-year median of 1.68. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 10.21. The Biotechnology industry median PB Ratio is 2.97. Restart Life Sciences' value of 1.84 is 38% below this industry median. Based on the distribution chart, Restart Life Sciences ranks #700 out of 1228 companies in the Biotechnology industry, which is below the industry midpoint.
How does Restart Life Sciences' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Restart Life Sciences ranks #700 out of 1228 companies for PB Ratio. This places Restart Life Sciences in the lower half of its industry. The industry median PB Ratio is 2.97. Restart Life Sciences' value of 1.84 is 38% below this benchmark. Historically, Restart Life Sciences' own PB Ratio has ranged from 0.42 to 10.21 over the past decade. While the company's 10-year median is 1.68 vs. the industry median of 2.97, Restart Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.97, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Restart Life Sciences's current PB Ratio of 1.84 is 38% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Restart Life Sciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Restart Life Sciences's current PB Ratio is 1.84, which is 10% above median its own 10-year median of 1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Restart Life Sciences stock overvalued right now?
Restart Life Sciences (NMLSF) has a current PB Ratio of 1.84. The current PB Ratio is 1.84, which is 10% above median its 10-year median of 1.68 and 38% below the Biotechnology industry median of 2.97. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Restart Life Sciences (NMLSF), the current PB Ratio is 1.84 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Restart Life Sciences Corp is a Canadian-based life sciences company dedicated to addressing health challenges with wellness solutions. Its brands include HolyCrap, BrainQ, Brain Balls.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NMLSF has been successfully added to your 